We have located links that may give you full text access.
HIV treatment scale-up: a critical step to controlling HIV epidemic in a resource-limited country.
Public Health 2018 November
OBJECTIVES: The study was conducted to determine the trend in HIV treatment coverage among people living with HIV and to evaluate effectiveness of the national antiretroviral treatment (ART) programme in reducing new infections in a mixed HIV epidemic nation, Nigeria.
STUDY DESIGN: Ecological cross-sectional study.
METHODS: The study utilized national HIV programme service data and National HIV/AIDS and Reproductive Health Survey (NARHS) data for 36 states and Federal Capital Territory from 2012 to 2015 in Nigeria. Chi-squared test for trend was conducted to determine differences in ART coverage across the years. We correlated 2015 ART coverage with HIV prevalence Annual Rate of Reduction (ARR) between 2012 and 2015. A linear regression model was fitted to predict the HIV prevalence ARR in relation to ART coverage and adjusted for the effect of socio-behavioral interventions (coverage of condom-use among male).
RESULTS: Nigeria has recorded steady progress with HIV treatment coverage with an annual rate of progress of 18.25%, P < 0.001; however, huge gaps still exist. Females and adults had higher odds of receiving ART. HIV prevalence annual reduction rate was higher for states that had higher ART coverage (r = 0.4; P = 0.02). Our analysis indicated that a 10% increase in ART coverage was associated with a 4% increase in the annual rate of reduction for HIV prevalence (adjusted β = 0.4; 95% confidence interval: 0.1-0.8; P = 0.01).
CONCLUSIONS: Regardless of the low ART coverage, our analysis supports the evidence base to inform accelerated access to HIV treatment for population Nigeria and other similar resource-limited settings to make ending HIV by 2030 a reality.
STUDY DESIGN: Ecological cross-sectional study.
METHODS: The study utilized national HIV programme service data and National HIV/AIDS and Reproductive Health Survey (NARHS) data for 36 states and Federal Capital Territory from 2012 to 2015 in Nigeria. Chi-squared test for trend was conducted to determine differences in ART coverage across the years. We correlated 2015 ART coverage with HIV prevalence Annual Rate of Reduction (ARR) between 2012 and 2015. A linear regression model was fitted to predict the HIV prevalence ARR in relation to ART coverage and adjusted for the effect of socio-behavioral interventions (coverage of condom-use among male).
RESULTS: Nigeria has recorded steady progress with HIV treatment coverage with an annual rate of progress of 18.25%, P < 0.001; however, huge gaps still exist. Females and adults had higher odds of receiving ART. HIV prevalence annual reduction rate was higher for states that had higher ART coverage (r = 0.4; P = 0.02). Our analysis indicated that a 10% increase in ART coverage was associated with a 4% increase in the annual rate of reduction for HIV prevalence (adjusted β = 0.4; 95% confidence interval: 0.1-0.8; P = 0.01).
CONCLUSIONS: Regardless of the low ART coverage, our analysis supports the evidence base to inform accelerated access to HIV treatment for population Nigeria and other similar resource-limited settings to make ending HIV by 2030 a reality.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app